<0> BioTime, Inc.Judith Segall, 510-521-3390 ext. 301orInvestor Contact:EVC Group, Inc.Gregory Gin, 862-236-0673James Dawson, 646-445-4800Doug Sherk, 415-652-9100 </0> , Inc. (NYSE MKT: BTX) announced ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...
BioTime completes expected acquisition of Asterias. Shares move 7% higher as BioTime broadens pipeline. Top management and a promising clinical program make BTX attractive. Shares of BioTime, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results